Changes in urinary dinor dihydro F₂-isoprostane metabolite concentrations, a marker of oxidative stress, during and following asthma exacerbations

References

• Montuschi P, Corradi M, Ciabattoni G, Nightingale J, Kharitonov SA, Barnes PJ. Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am J Respir Crit Care Med 1999; 160: 216–220
   PubMed Web of Science ®Google Scholar
• Wood LG, Garg ML, Simpson JL, Mori TA, Croft KD, Wark PA, Gibson PG. Induced sputum 8-isoprostane concentrations in inflammatory airway diseases. Am J Respir Crit Care Med 2005; 171: 426–430
   PubMed Web of Science ®Google Scholar
• Dworski R, Murray JJ, Roberts LJ, Oates JA, Morrow JD, Fisher L, Sheller JR. Allergen-induced synthesis of F(2)-isoprostanes in atopic asthmatics. Evidence for oxidant stress. Am J Respir Crit Care Med 1999; 160: 1947–1951
   PubMed Web of Science ®Google Scholar
• Shahid SK, Kharitonov SA, Wilson NM, Bush A, Barnes PJ. Exhaled 8-isoprostane in childhood asthma. Respir Res 2005; 6: 79
   PubMed Web of Science ®Google Scholar
• Baraldi E, Ghiro L, Piovan V, Carraro S, Ciabattoni G, Barnes PJ, Montuschi P. Increased exhaled 8-isoprostane in childhood asthma. Chest 2003; 124: 25–31
   PubMed Web of Science ®Google Scholar
• Zanconato S, Carraro S, Corradi M, Alinovi R, Pasquale MF, Piacentini G, Zacchello F, Baraldi E. Leukotrienes and 8-isoprostane in exhaled breath condensate of children with stable and unstable asthma. J Allergy Clin Immunol 2004; 113: 257–263
   PubMed Web of Science ®Google Scholar
• Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990; 87: 9383–9387
   PubMed Web of Science ®Google Scholar
• Dworski R, Roberts LJ, Murray JJ, Morrow JD, Hartert TV, Sheller JR. Assessment of oxidant stress in allergic asthma by measurement of the major urinary metabolite of F2-isoprostane, 15-F2t-IsoP (8-iso-PGF2alpha). Clin Exp Allergy 2001; 31: 387–390
   PubMed Web of Science ®Google Scholar
• Montuschi P, Barnes PJ, Roberts LJ. Isoprostanes: markers and mediators of oxidative stress. FASEB J 2004; 18: 1791–1800
   PubMed Web of Science ®Google Scholar
• McAdams SA, Cordeiro ML. Simple selected ion monitoring capillary gas chromatographic-mass spectrometric method for the determination of cotinine in serum, urine and oral samples. J Chromatogr 1993; 615: 148–153
   PubMed Web of Science ®Google Scholar
• Haufroid V, Lison D. Urinary cotinine as a tobacco-smoke exposure index: a minireview. Int Arch Occup Environ Health 1998; 71: 162–168
   PubMed Web of Science ®Google Scholar
• Hariharan M, VanNoord T. Liquid-chromatographic determination of nicotine and cotinine in urine from passive smokers: comparison with gas chromatography with a nitrogen-specific detector. Clin Chem 1991; 37: 1276–1280
   PubMed Web of Science ®Google Scholar
• Global initiative for asthma: Global Strategy for Asthma Management and Prevention. Available online at: http://www.ginasthma.org/Guidelineitem.asp??l1=2&l2=1&intId=60, Accessed 28 March 2007.
   Google Scholar
• Togias A, Horowitz E, Joyner D, Guydon L, Malveaux F. Evaluating the factors that relate to asthma severity in adolescents. Int Arch Allergy Immunol 1997; 113: 87–95
   PubMedGoogle Scholar
• Morrow JD, Zackert WE, Yang JP, Kurhts EH, Callewaert D, Dworski R, Kanai K, Taber D, Moore K, Oates JA, Roberts LJ. Quantification of the major urinary metabolite of 15-F2t-isoprostane (8-iso-PGF2alpha) by a stable isotope dilution mass spectrometric assay. Anal Biochem 1999; 269: 326–331
   PubMed Web of Science ®Google Scholar
• Corradi M, Folesani G, Andreoli R, Manini P, Bodini A, Piacentini G, Carraro S, Zanconato S, Baraldi E. Aldehydes and glutathione in exhaled breath condensate of children with asthma exacerbation. Am J Respir Crit Care Med 2003; 167: 395–399
   PubMed Web of Science ®Google Scholar
• De Raeve HR, Thunnissen FB, Kaneko FT, Guo FH, Lewis M, Kavuru MS, Secic M, Thomassen MJ, Erzurum SC. Decreased Cu,Zn-SOD activity in asthmatic airway epithelium: correction by inhaled corticosteroid in vivo. Am J Physiol 1997; 272: L148–L154
   PubMedGoogle Scholar
• Sadowska AM, van Overveld FJ, Gorecka D, Zdral A, Filewska M, Demkow UA, Luyten C, Saenen E, Zielinski J, De Backer WA. The interrelationship between markers of inflammation and oxidative stress in chronic obstructive pulmonary disease: modulation by inhaled steroids and antioxidant. Respir Med 2005; 99: 241–249
   PubMed Web of Science ®Google Scholar
• Kavanagh RJ, Kam PC. Lazaroids: efficacy and mechanism of action of the 21-aminosteroids in neuroprotection. Br J Anaesth 2001; 86: 110–119
   PubMed Web of Science ®Google Scholar
• van den Toorn LM, Overbeek SE, de Jongste JC, Leman K, Hoogsteden HC, Prins JB. Airway inflammation is present during clinical remission of atopic asthma. Am J Respir Crit Care Med 2001; 164: 2107–2113
   PubMed Web of Science ®Google Scholar
• Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC, Chinchilli VM, Craig TJ, Dimango EA, Deykin A, Fagan JK, Fish JE, Ford JG, Kraft M, Lemanske RF, Jr, Leone FT, Martin RJ, Mauger EA, Pesola GR, Peters SP, Rollings NJ, Szefler SJ, Wechsler ME, Israel E. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005; 352: 1519–1528
   PubMed Web of Science ®Google Scholar
• Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, Zeiger RS, Larsen G, Spahn JD, Bacharier LB, Bloomberg GR, Guilbert TW, Heldt G, Morgan WJ, Moss MH, Sorkness CA, Taussig LM. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115: 233–242
   PubMed Web of Science ®Google Scholar
• Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352: 2163–2173
   PubMed Web of Science ®Google Scholar
• Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL study group. Am J Respir Crit Care Med 1999; 159: 1043–1051
   PubMed Web of Science ®Google Scholar
• Davies SS, Zackert W, Luo Y, Cunningham CC, Frisard M, Roberts LJ. Quantification of dinor, dihydro metabolites of F(2)-isoprostanes in urine by liquid chromatography/tandem mass spectrometry. Anal Biochem 2006; 348: 185–191
   PubMedGoogle Scholar
• Jayaram L, Pizzichini MM, Cook RJ, Boulet LP, Lemiere C, Pizzichini E, Cartier A, Hussack P, Goldsmith CH, Laviolette M, Parameswaran K, Hargreave FE. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27: 483–494
   PubMed Web of Science ®Google Scholar
• Montuschi P. Indirect monitoring of lung inflammation. Nat Rev Drug Discov 2002; 1: 238–242
   PubMed Web of Science ®Google Scholar
• Gillissen A, Wickenburg D, van Zwoll D, Schultze-Werninghaus G. Beta-2-agonists have antioxidant function in vitro. 2. The effect of beta-2-agonists on oxidant-mediated cytotoxicity and on superoxide anion generated by human polymorphonuclear leukocytes. Respiration 1997; 64: 23–28
   PubMedGoogle Scholar
• Gillissen A, Jaworska M, Scharling B, van Zwoll D, Schultze-Werninghaus G. Beta-2-agonists have antioxidant function in vitro. 1. Inhibition of superoxide anion, hydrogen peroxide, hypochlorous acid and hydroxyl radical. Respiration 1997; 64: 16–22
   PubMed Web of Science ®Google Scholar